Xencor, Inc. (XNCR) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Xencor, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.284 -- 00:00:04.710 Thank you for joining this session. My name is Alex Stranahan. 00:00:04.710 -- 00:00:10.417 I cover SMID Biotech at Bank of America, and I'm the analyst covering Zencore. 00:00:10.417 -- 00:00:15.603 And it's my pleasure to introduce Basil DeHyatt, President and CEO of Zencore, and Dane 00:00:15.603 -- 00:00:18.327 Leone, Chief Strategy Officer. Guys, thanks for being here. 00:00:18.327 -- 00:00:21.931 Hey, thanks so much for having us. Looking forward to the discussion. 00:00:21.931 -- 00:00:27.117 So, you know, maybe, Basil, like, just at a high level, what gets you most 00:00:27.117 -- 00:00:33.109 excited about the company? And, you know, which asset is your favorite? 00:00:33.109 -- 00:00:38.236 Well, I think that the tempo of data that we have starting the 00:00:38.236 -- 00:00:41.577 second half of this year with our XF819, 00:00:41.860 -- 00:00:45.585 you know, phase one sort of second readout where we hope to have our recommended phase 00:00:45.585 -- 00:00:50.611 three dose, a clear pivotal plan, and robust efficacy and tolerability data in 00:00:50.611 -- 00:00:54.216 our target dose range, that is, you know, coming on really soon. 00:00:54.216 -- 00:00:58.641 So I'm very excited about that. And that's really the beginning of a flow of data that 00:00:58.641 -- 00:01:04.100 we're going to have our second oncology solid tumor, bispecific 00:01:04.100 -- 00:01:05.602 XMAP541 00:01:05.602 -- 00:01:10.609 in gynecologic and GCT, and then followed in the new year in 00:01:10.609 -- 00:01:13.794 2027 by our first bispecific 00:01:13.794 -- 00:01:18.981 TL1A-containing molecule, XMAP412. We expect to have healthy volunteer 00:01:18.981 -- 00:01:23.647 PKPD and safety and immunogenicity data for that one. 00:01:23.647 -- 00:01:2...